Annual incidence of colorectal cancer among patients with average risk in the United States between 2017 and 2023.

B Brad Stieber (Exact Sciences Corporation, Madison, WI) M Mallik Greene (Exact Sciences Corporation, Madison, WI) Q Quang Anh Le (Exact Sciences Corporation, Madison, WI) J Joshua Mou (Exact Sciences Corporation, Madison, WI) L Lakshya Sakthisivabalan (Exact Sciences Corporation, Madison, WI) D Danielle Lynch (Exact Sciences Corporation, Madison, WI) A A Burak Ozbay (Exact Sciences Corporation, Madison, WI) J Joseph LeMaster (DARTNet Insitute, Kansas City, KS) I Igor Stukalin (University of Calgary, Cumming School of Medicine, Calgary, AB, Canada) J Joseph Anderson (Dartmouth College Geisel School of Medicine, Lebanon, NH) P Paul J. Limburg (Exact Sciences Corp., Madison, WI)

Abstract

83 Background: Colorectal cancer (CRC) is the second most common cause of cancer-related mortality and third most common cancer in the United States. In 2021, 141,902 new cases of CRC were reported. With recent increases in early onset of CRC incidence, a shift in patterns amongst various demographics has been observed. Together with an estimated 60% increase in burden of CRC globally, it is important to continuously assess the nationwide incidence rates and monitor the changing patterns. In this study, we examined the annual incidence rates of CRC in average risk adults using a large national claims database and report patterns of incidence based on various demographic characteristics. Methods: CRC diagnoses were retrospectively identified from a large national claims database, which covers over 165 million lives and is representative of the U.S. population, for each calendar year during the study period from 2017 to 2023. Individuals aged 45 to 75 years, with an average risk of CRC before each index calendar year were included in the study. Individuals were required to be continuously enrolled in the same health plan for at least 1 year prior to and 1 year following the index year. Annual CRC incidence rates per 100,000 people were calculated for each year from 2017 to 2023 within various subgroups based on baseline demographics. Results: Overall, annual CRC incidences remained consistent during the study period with 186.86 (95% CI, 184.87-188.86) cases in 2017 and 183.40 (95% CI, 181.32-185.5) cases in 2023 per 100,000. Among younger adults aged 45-49 years, the annual CRC incidence increased by 66% from 2017 (92.04 cases/100,000) to 2023 (153.12 cases/100,000). Conversely, annual CRC incidence decreased by 25% between 2017 (328.52 cases/100,000) and 2023 (244.93/100,000) in older adults aged 65-75 years. Over the study period, CRC incidence in men was higher than women with an overall rate ratio (RR) of 1.206 (95% CI, 1.122-1.297). African American adults had higher CRC incidence than White Americans with an overall rate ratio (RR) of 1.216 (95% CI, 1.152-1.283). Conclusions: Based on this large study of national claims data, CRC incidence rates remained relatively stable in the total population among average-risk patients from 2017 to 2023. The continuing increase in recommended CRC screening utilization showed a decreased incidence rate in the older population, while observing increased incidences among younger patients.

Article Details

Volume / Issue Vol. 43, Issue 4_suppl
Published February 01, 2025
Pages 83-83
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (11)

B

Brad Stieber

Exact Sciences Corporation, Madison, WI

M

Mallik Greene

Exact Sciences Corporation, Madison, WI

Q

Quang Anh Le

Exact Sciences Corporation, Madison, WI

J

Joshua Mou

Exact Sciences Corporation, Madison, WI

L

Lakshya Sakthisivabalan

Exact Sciences Corporation, Madison, WI

D

Danielle Lynch

Exact Sciences Corporation, Madison, WI

A

A Burak Ozbay

Exact Sciences Corporation, Madison, WI

J

Joseph LeMaster

DARTNet Insitute, Kansas City, KS

I

Igor Stukalin

University of Calgary, Cumming School of Medicine, Calgary, AB, Canada

J

Joseph Anderson

Dartmouth College Geisel School of Medicine, Lebanon, NH

P

Paul J. Limburg

Exact Sciences Corp., Madison, WI